Cost Effectiveness and Resource Allocation

Table 4 Health utility value

From: Cost-utility analysis of olaparib assisted targeted therapy for BRCA mutation HER2-negative early breast cancer in China and in the United States

Parameters name	Base	Range	Mean	SD	Distribution	Source
PFS
China	0.81	± 5%	0.81	0.23	Beta	[12]
The United States	0.868	± 5%	0.868	0.135	Beta	[14]
PD
China	0.74	± 5%	0.74	0.27	Beta	[12]
The United States	0.786	± 5%	0.786	0.0393	Beta	[9]

SD Standardized Deviation; PFS Progression-Free survival; PD Disease Progression

Back to article page

ISSN: 1478-7547

Contact us

General enquiries: journalsubmissions@springernature.com